AstraZeneca Says PT027 Phase 3 Asthma Trials Met Primary Endpoints
09 Setembro 2021 - 3:44AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Thursday that the PT027 asthma treatment
showed significant benefits for asthma patients in Phase 3
trials.
The U.K. pharmaceutical giant said PT027--a fixed-dose
combination of albuterol and budesonide--met all primary endpoints
and showed statistically significant benefits in patients with
asthma versus individual components albuterol, also known as
salbutamol, and budesonide.
The company said the trials "demonstrate an albuterol/budesonide
rescue inhaler can address inflammation and prevent exacerbations,
making PT027 an important potential new treatment option for
patients."
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 09, 2021 02:29 ET (06:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
